DrugPatentWatch Database Preview
Details for Patent: 8,163,904
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
Which drugs does patent 8,163,904 protect, and when does it expire?
Patent 8,163,904 protects TASIGNA and is included in one NDA.
Protection for TASIGNA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has fifty-three patent family members in thirty-four countries.
Summary for Patent: 8,163,904
| Title: | Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-- 3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide |
| Abstract: | Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]- -3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide are prepared by various processes. |
| Inventor(s): | Manley; Paul W (Arlesheim, CH), Shieh; Wen-Chung (Berkeley Heights, NJ), Sutton; Paul Allen (Parsippany, NJ), Karpinski; Piotr H (Lincoln Park, NJ), Wu; Raeann (Pine Brook, NJ), Monnier; Stephanie (Raedersheim, FR), Brozio; Jorg (Basel, CH) |
| Assignee: | Novartis AG (Basel, CH) Novartis Pharma GmbH (Vienna, AT) |
| Application Number: | 11/995,898 |
|
Patent Claim Types: see list of patent claims | Compound; Use; Formulation; Composition; |
Drugs Protected by US Patent 8,163,904
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | TASIGNA | nilotinib hydrochloride | CAPSULE;ORAL | 022068-003 | Mar 22, 2018 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||||
| Novartis | TASIGNA | nilotinib hydrochloride | CAPSULE;ORAL | 022068-002 | Jun 17, 2010 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||||
| Novartis | TASIGNA | nilotinib hydrochloride | CAPSULE;ORAL | 022068-001 | Oct 29, 2007 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,163,904
| PCT Information | |||
| PCT Filed | July 18, 2006 | PCT Application Number: | PCT/US2006/027878 |
| PCT Publication Date: | February 08, 2007 | PCT Publication Number: | WO2007/015871 |
International Family Members for US Patent 8,163,904
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 057467 | Start Trial | |||
| Austria | 514689 | Start Trial | |||
| Australia | 2006276205 | Start Trial | |||
| Australia | 2010241419 | Start Trial | |||
| Australia | 2012203844 | Start Trial | |||
| Brazil | PI0613605 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
